DUSA Pharmaceuticals Revenue and Competitors

Boston, MA USA

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • DUSA Pharmaceuticals's estimated annual revenue is currently $35.6M per year.(i)
  • DUSA Pharmaceuticals's estimated revenue per employee is $201,000

Employee Data

  • DUSA Pharmaceuticals has 177 Employees.(i)

DUSA Pharmaceuticals's People

NameTitleEmail/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$413.3M3240%$634MN/A
#2
$47.8M2380%N/AN/A
#3
$2.4M12-52%N/AN/A
#4
$25.7M12839%N/AN/A
#5
$12.9M64129%N/AN/A
#6
$23.9M1198%$113MN/A
#7
$0.3M30%N/AN/A
#8
$10.3M51-14%N/AN/A
#9
$1.8M367-4%$538MN/A
#10
$50M2493%N/AN/A
Add Company

What Is DUSA Pharmaceuticals?

Development Associates, a proprietorship formed in 1985 which provides consulting and venture support services to manage and finance early-stage technology-based companies DUSA Pharmaceuticals, Inc.® is a fully integrated specialty pharmaceutical company focused primarily on the development and marketing of its Levulan® Kerastick® (aminolevulinic acid HCl) for Topical Solution, 20% photodynamic therapy (PDT) technology platform used in conjunction with it’s proprietary light source, the BLU-U® Blue Light Photodynamic Therapy Illuminator. LEVULAN KERASTICK in combination with the BLU-U is approved by the U.S. Food and Drug Administration for the treatment of minimally to moderately thick actinic keratoses (AKs) of the face or scalp

keywords:N/A

N/A

Total Funding

177

Number of Employees

$35.6M

Revenue (est)

N/A

Employee Growth %

N/A

Valuation

N/A

Accelerator

DUSA Pharmaceuticals News

2022-04-17 - Actinic Keratosis Therapeutics Market Size 2022-2029| Key ...

Dusa Pharmaceuticals; Novartis; Perrigo; Leo Pharma; Bausch Health; Taro Pharmaceutical; Galderma (nestle); Biofrontera; Almirall; Tolmar Pharmaceutical.

2022-04-13 - Actinic Keratosis Treatment Market Registering a CAGR of 4.2% from 2019 to 2026.

... Inc., LEO Pharma A/S, Mylan N.V., Novartis AG, Stanford Chemicals, and Sun Pharmaceutical Industries Ltd. (DUSA Pharmaceuticals, Inc.).

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$53.8M181-1%N/A
#2
N/A18145%N/A
#3
$32M1822%N/A
#4
$42.5M18428%N/A
#5
$54.9M1855%N/A